A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Disturbances in N-methyl-D-aspartate (NMDA) receptor activity may play a role in attention-deficit/hyperactivity disorder (ADHD). OBJECTIVE: This study is a preliminary evaluation of the safety, pharmacokinetics, and effectiveness of the NMDA receptor antagonist memantine in pediatric ADHD. METHODS: An open-label, dose-finding, 8-week, trial in outpatients 6-12 years old with ADHD combined type. Memantine oral solution (2 mg/mL) was titrated to 10 mg/day (n = 8) or 20 mg/day (n = 8). Safety data and blood samples for pharmacokinetic analyses were collected. The ADHD Rating Scale-IV (ADHD-IV) and Clinical Global Impression of Severity (CGI-S) scale measured the effectiveness of memantine. RESULTS: There were no discontinuations due to adverse events (AEs), serious AEs, deaths, or suicides. Most AEs were mild and occurred during the first week of treatment. The 20 mg/day memantine dose was associated with a higher rate of completion and larger mean improvement on the ADHD-IV and CGI-S than 10 mg/day memantine. Pharmacokinetic analyses suggest response to memantine may be dose-dependent beyond an initial threshold concentration. CONCLUSIONS: This pilot study suggests that a memantine dose of 20 mg/day may be a safe and possibly effective treatment for pediatric ADHD. Further investigations of memantine in ADHD appear to be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Attention-deficit hyperactivity disorder
Biederman, J., & Faraone, S. V. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66915-2 · Cited by 1,463
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Self-citationEvidence-Based Assessment of Attention Deficit Hyperactivity Disorder in Children and Adolescents
Pelham, Jr., Fabiano, G. A., & Massetti, G. M. (2005) · Journal of Clinical Child & Adolescent Psychology · doi:10.1207/s15374424jccp3403_5 · Cited by 803 · cited 1×
“…the combined type, which includes ( 20 significant symptoms of both inattentiveness and hyperactivity–impulsivity (Wilens et al. including poor performance in school and work, difficulty with peer and family relationships, and antisocial behavior (Biederman ( and Faraone 2005; Pelham et al. 2005).”
Kessler, R. C., Adler, L. A., Barkley, R., Biederman, J., Conners, C. K., Faraone, S. V., Greenhill, L. L., Jaeger, S., Secnik, K., Spencer, T., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.001 · Cited by 663 · cited 3×
“Recent estimates about 40–60% of those with ADHD in childhood continue to experience some impairing symptoms as adults (Kessler et al. 2005; Faraone et al. 2006) It is well established that dopamine and norepinephrine abnormalities may be present in ADHD, and all current U.S. drugs labeled for use…”
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539 · cited 1×
“…b.i.d.), the safety of memantine was comparable to placebo, as indicated by similar adverse event profiles and frequency discontinuation due to adverse events Winblad and Poritis 1999; Orgogozo et al. 2002; Wilcock et al. 2002; Reisberg et al. 2003; Tariot et al. 2004; Forest Pharmaceuticals 2005).”
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381 · cited 1×
“…b.i.d.), the safety of memantine was comparable to placebo, as indicated by similar adverse event profiles and frequency discontinuation due to adverse events Winblad and Poritis 1999; Orgogozo et al. 2002; Wilcock et al. 2002; Reisberg et al. 2003; Tariot et al. 2004; Forest Pharmaceuticals 2005).”
Cited by
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Cognition enhancers between treating and doping the mind
Lanni, C., Lenzken, S. C., Pascale, A., Del Vecchio, I., Racchi, M., Pistoia, F., & Govoni, S. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.02.004 · Cited by 166
“[71] Findling RL, McNamara NK, Stansbrey RJ, Maxhimer R, Periclou A, Mann A, et al.”
BackgroundGrossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys
Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71
“Memantine is an uncompetitive NMDA receptor antagonist, used in Alzheimer disease [Reisberg et al., 2003], in patients with either idiopathic pervasive developmental disorder (PDD) [Chez et al., 2007] and in patients with ADHD [Findling et al., 2007].”
BackgroundNonstimulant Treatments for ADHD
Newcorn, J. H., Krone, B., & Dittmann, R. W. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.005 · Cited by 29
Metadata
- Authors
- Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., & Graham, S. M.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2007-02
- Volume
- 17
- Issue
- 1
- Pages
- 19-33
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2040478347
- Cited by
- 76
- References
- 8
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type. https://app.cochat.ai/papers/10.1089/cap.2006.0044
- The paper
- Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., & Graham, S. M. (2007). A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2006.0044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.